Abstract:Recombinant adeno-associated virus (rAAV) is the most widely used viral vector for in vivo human gene therapy. To ensure safety and efficacy of gene therapy products, a comprehensive analytical profile of the rAAVs is needed, which provides crucial information for therapeutic development and manufacturing. Besides information on rAAV quantities and possible contaminating DNA and protein species, assessing rAAV quality is of utmost importance. In vitro biopotency and methods to determine the full/empty ratio of rAAV capsids are commonly applied, but methods to assess the integrity of the viral genome are still rarely used. Here we describe an orthogonal approach to characterize rAAV quality. Two biologically different rAAV9s from different stages of the bioprocess, generated each with two different transfection reagents, were investigated. In vitro biopotency tests in all cases demonstrated that rAAV9s generated with transfection reagent FectoVIR® possessed a higher biological activity. Mass-based analytical methods, such as sedimentation velocity analytical ultracentrifugation (AUC) and mass photometry, showed a high share of full capsids (>80 %) at late process stages but did not detect any differences in the rAAV9s from the different transfection reagents. Multiplex dPCR and Nanopore long-read sequencing both demonstrated that, also in late-stage process samples, sample heterogeneity was relatively high with a rather small share of full-length transgenes of ∼10-40 %. Intriguingly, both methods detected a higher share of complete transgenes in rAAV9 generated with transfection reagent FectoVIR® instead of Polyethylenimine (PEI), and thereby explain the differences already observed in the biopotency assays. This study therefore emphasizes the necessity to utilize multiple, orthogonal methods to gain a better understanding of recombinantly manufactured AAVs.

Assessment of cell-binding capacity of shed rAAV particles after gene therapy vector administration: implications for environmental risk and hygiene recommendations

Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer

Understanding AAV vector immunogenicity: from particle to patient

Human Immune Responses to Adeno-Associated Virus (AAV) Vectors

Intracellular trafficking of adeno-associated virus (AAV) vectors: challenges and future directions

Systemic Toxicity of Recombinant Adeno-Associated Virus Gene Therapy Vectors.

A shedding analysis after AAV8 CNS injection revealed fragmented viral DNA without evidence of functional AAV particles in mice

Immunogenicity risk assessment of empty capsids present in adeno-associated viral vectors using predictive innate immune responses

Evaluating the state of the science for adeno-associated virus integration: An integrated perspective

Adeno-associated Virus (AAV) versus Immune Response

Characterization of residual microRNAs in AAV vector batches produced in HEK293 mammalian cells and Sf9 insect cells

Proteomic Landscape of Adeno-Associated Virus (AAV)-Producing HEK293 Cells

Insight into the Degradation Pathways of an AAV9

Adeno-associated virus as a delivery vector for gene therapy of human diseases

Orthogonal characterization of rAAV9 reveals unexpected transgene heterogeneity

Next-generation strategies to improve safety and efficacy of adeno-associated virus-based gene therapy for hemophilia: lessons from clinical trials in other gene therapies

Prevalence study of cellular capsid-specific immune responses to AAV2, 4, 5, 8, 9 and rh10 in healthy donors

Immune responses to AAV in clinical trials

Towards Clinical Implementation of Adeno-Associated Virus (AAV) Vectors for Cancer Gene Therapy: Current Status and Future Perspectives

Recombinant adeno-associated virus as delivery vector for gene therapy--a review.

The Impact of Pre-existing Immunity on the Non-clinical Pharmacodynamics of AAV5-Based Gene Therapy